Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 1 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 27, 2020 23:53 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001363 · ownership.xml · derivative · entry 3 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:53 UTC |
Loerop JamesEVP Business Development
|
GrantRestricted Stock Unit · Derivative | 4,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001362 · ownership.xml · derivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 4,700 shares Expires not disclosed F1 · derivative.exercise_date: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event. F1 · derivative.expiration_date: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:52 UTC |
VOGT SUSAN L NDirector
|
GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001361 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,652 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:51 UTC |
Larsen Glenn R.Director
|
GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001360 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,697 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:49 UTC |
Cheung SylviaChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 11,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001358 · ownership.xml · derivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:50 UTC |
Bower Joseph L.Director
|
GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001359 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,117 F1 · security: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in five equal annual installments each occurring within 60 days of the anniversary of such event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:48 UTC |
Blanchard Cheryl RDirector
|
GrantRestricted Stock Unit · Derivative | 4,231 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001357 · ownership.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,231 Underlying: Common Stock · 4,231 shares Expires not disclosed F1 · derivative.exercise_date: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). "Term" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO. F1 · derivative.expiration_date: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). "Term" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:47 UTC |
Thompson Jeffery SDirector
|
GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001356 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,949 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 22:12 UTC |
Cheung SylviaChief Financial Officer
|
Tax withholdingCommon Stock | 579 | $40.59 | $23,501.61 |
DisclosureSEC source: 0001171843-20-000783 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,162 F1 · shares: Reflects an aggregate of 579 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested on February 4, 2020. F2 · price: Reflects the closing price of the ANIK common stock on February 4, 2020, the trading day on which the vesting of restricted shares gave rise to tax withholding obligations. Read SEC document |
| November 27, 2019 Filed Nov 29, 2019 21:06 UTC |
Bower Joseph L.Director
|
GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-007869 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,010 F1 · shares: The shares of common stock of Anika Therapeutics, Inc. were given by Dr. Bower as a bona fide gift to the President and Fellows of Harvard College, a 501(c)(3) non-profit organization, for no valuable consideration on November 27, 2019. F1 · price: The shares of common stock of Anika Therapeutics, Inc. were given by Dr. Bower as a bona fide gift to the President and Fellows of Harvard College, a 501(c)(3) non-profit organization, for no valuable consideration on November 27, 2019. Read SEC document |
| November 08, 2019 Filed Nov 8, 2019 22:40 UTC |
Cheung SylviaChief Financial Officer
|
SaleCommon Stock | 20,000 | $59.71 | $1,194,200.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,741 F3 · security: On November 8, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung sold 20,000 shares in multiple trades ranging from $59.00 to $60.40, a portion of which sale covered the tax liability associated with the SARs exercise. The price reported above reflects the weighted average sale price. Ms. Cheung undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. F3 · price: On November 8, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung sold 20,000 shares in multiple trades ranging from $59.00 to $60.40, a portion of which sale covered the tax liability associated with the SARs exercise. The price reported above reflects the weighted average sale price. Ms. Cheung undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 35,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · derivative · entry 4 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2020-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On November 6, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung exercised stock appreciation rights ("SARS") granted on January 26, 2010 vesting in four equal annual installments beginning January 26, 2011 and expiring on January 26, 2020. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC |
Cheung SylviaChief Financial Officer
|
Tax withholdingCommon Stock | 3,681 | $60.48 | $222,626.88 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,741 F2 · security: Reflects 3,681 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on November 6, 2019. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 22:40 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionCommon Stock | 35,000 | $6.36 | $222,600.00 |
DisclosureSEC source: 0001171843-19-007390 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 6, 2019, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on May 7, 2019, Ms. Cheung exercised stock appreciation rights ("SARS") granted on January 26, 2010 vesting in four equal annual installments beginning January 26, 2011 and expiring on January 26, 2020. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 20:06 UTC |
Finnerty ThomasEVP Human Resources
|
Tax withholdingCommon Stock | 672 | $69.67 | $46,818.24 |
DisclosureSEC source: 0001171843-19-007081 · ownership.xml · nonDerivative · entry 1 Finnerty Thomas · CIK 0001720871 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,128 F1 · shares: Reflects an aggregate of 672 shares of common stock retained by the Issuer to satisfy tax withholding obligations. F2 · price: Reflects the closing price of the ANIK common stock on October 30, 2019, the trading day on which the vesting of restricted shares occurred giving rise to tax withholding obligations. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 20:05 UTC |
Larsen Glenn R.Director
|
SaleCommon Stock | 4,355 | $57.21 | $249,149.55 |
DisclosureSEC source: 0001171843-19-005733 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 F1 · price: Represents the weighted average sales price. The shares were sold on 8/28/19 at prices ranging from $57.14 to $57.34 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 20:05 UTC |
Bower Joseph L.Director
|
SaleCommon Stock | 1,994 | $55.57 | $110,806.58 |
DisclosureSEC source: 0001171843-19-005617 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,010 F1 · price: Represents the weighted average sales price. The shares were sold on 8/20/19 at prices ranging from $55.50 to $55.66 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 20:06 UTC |
Thompson Jeffery SDirector
|
SaleCommon Stock | 4,843 | $56.66 | $274,404.38 |
DisclosureSEC source: 0001171843-19-005414 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,842 F1 · price: Represents the weighted average sales price. The shares were sold on 8/8/19 at prices ranging from $56.65 to $56.75 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 20:06 UTC |
LAND RAYMOND JDirector
|
SaleCommon Stock | 3,000 | $55.44 | $166,320.00 |
DisclosureSEC source: 0001171843-19-004979 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,992 F1 · shares: On July 29, 2019, Mr. Land sold 3,000 shares in accordance with a previously-executed 10b5-1 Sales Plan. Read SEC document |
| July 27, 2019 Filed Jul 30, 2019 20:05 UTC |
Darling Joseph GDirector · President and CEO; Director
|
Tax withholdingCommon Stock | 2,147 | $55.85 | $119,909.95 |
DisclosureSEC source: 0001171843-19-004978 · ownership.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,289 F1 · shares: Reflects an aggregate of 2,147 shares of common stock retained by the Issuer to satisfy tax withholding obligations. F2 · price: Reflects the closing price of the ANIK common stock on July 26, 2019, the last trading day prior to the vesting of restricted shares giving rise to tax withholding obligations. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:10 UTC |
Loerop JamesEVP Business Development
|
GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $40.67 | $0.00 |
DisclosureSEC source: 0001171843-19-004474 · ownership.xml · derivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-07-08 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning July 8, 2020. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:10 UTC |
Loerop JamesEVP Business Development
|
GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-004474 · ownership.xml · derivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 13:30 UTC |
Darling Joseph GDirector · President and CEO; Director
|
PurchaseCommon Stock | 1,000 | $33.20 | $33,200.00 |
DisclosureSEC source: 0001171843-19-001414 · ownership.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,436 Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:33 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantStock Option (Right to Buy) · Derivative | 2,873 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001387 · ownership.xml · derivative · entry 2 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,873 Underlying: Common Stock · 2,873 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:34 UTC |
Hague RichardChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001388 · ownership.xml · derivative · entry 2 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:32 UTC |
Darling Joseph GDirector · President and CEO; Director
|
GrantStock Option (Right to Buy) · Derivative | 7,609 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001386 · ownership.xml · derivative · entry 2 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,609 Underlying: Common Stock · 7,609 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:32 UTC |
Cheung SylviaChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,609 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001385 · ownership.xml · derivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,609 Underlying: Common Stock · 7,609 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:30 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001382 · ownership.xml · derivative · entry 2 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 63.9% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:33 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001387 · ownership.xml · derivative · entry 1 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:36 UTC |
VOGT SUSAN L NDirector
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001392 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,545 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:36 UTC |
Thompson Jeffery SDirector
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001391 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,685 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:35 UTC |
Larsen Glenn R.Director
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001390 · ownership.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,945 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:34 UTC |
LAND RAYMOND JDirector
|
SaleCommon Stock | 4,000 | $33.06 | $132,240.00 |
DisclosureSEC source: 0001171843-19-001389 · ownership.xml · nonDerivative · entry 2 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,992 F2 · price: On February 26, 2019, Mr. Land sold 4,000 shares in multiple trades ranging from $32.76 to $33.13. The price reported above reflects the weighted average sales price. Mr. Land undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:34 UTC |
LAND RAYMOND JDirector
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001389 · ownership.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,992 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:34 UTC |
Hague RichardChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001388 · ownership.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:32 UTC |
Darling Joseph GDirector · President and CEO; Director
|
GrantRestricted Stock Unit · Derivative | 63,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001386 · ownership.xml · derivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020, provided that the first installment of shares hereunder shall be delivered upon the first to occur of Mr. Darling's (a) death, (b) disability, (c) separation from service (as defined by the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the "Plan")), or (d) a Change in Control (as defined by the Plan). F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020, provided that the first installment of shares hereunder shall be delivered upon the first to occur of Mr. Darling's (a) death, (b) disability, (c) separation from service (as defined by the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the "Plan")), or (d) a Change in Control (as defined by the Plan). Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:32 UTC |
Cheung SylviaChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001385 · ownership.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:31 UTC |
Bower Joseph L.Director
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001384 · ownership.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,004 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:31 UTC |
Blanchard Cheryl RDirector
|
GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001383 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,466 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:30 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001382 · ownership.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 14:15 UTC |
Cheung SylviaChief Financial Officer
|
Tax withholdingCommon Stock | 607 | $38.10 | $23,126.70 |
DisclosureSEC source: 0001171843-19-000756 · ownership.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,422 F2 · shares: Reflects an aggregate of 607 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 4, 2019. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 14:15 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
Tax withholdingCommon Stock | 685 | $38.10 | $26,098.50 |
DisclosureSEC source: 0001171843-19-000755 · ownership.xml · nonDerivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,575 F1 · shares: Reflects an aggregate of 685 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 4, 2019. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 13:38 UTC |
Hague RichardChief Commercial Officer
|
Tax withholdingCommon Stock | 685 | $38.10 | $26,098.50 |
DisclosureSEC source: 0001171843-19-000754 · ownership.xml · nonDerivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,419 F1 · shares: Reflects an aggregate of 685 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 4, 2019. Read SEC document |
| February 03, 2019 Filed Feb 6, 2019 14:15 UTC |
Cheung SylviaChief Financial Officer
|
Tax withholdingCommon Stock | 579 | $37.97 | $21,984.63 |
DisclosureSEC source: 0001171843-19-000756 · ownership.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,029 F1 · shares: Reflects an aggregate of 579 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 3, 2019. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 20:05 UTC |
Hague RichardChief Commercial Officer
|
Tax withholdingCommon Stock | 1,546 | $35.55 | $54,960.30 |
DisclosureSEC source: 0001171843-18-007354 · ownership.xml · nonDerivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,104 F1 · shares: Reflects an aggregate of 1,546 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested on October 26, 2018. Read SEC document |
| October 23, 2018 Filed Oct 25, 2018 20:10 UTC |
VOGT SUSAN L NDirector
|
GrantCommon Stock | 3,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-007240 · ownership.xml · nonDerivative · entry 1 VOGT SUSAN L N · CIK 0001191270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest immediately prior to the Anika Therapeutics, Inc. 2019 Annual Meeting of Stockholders. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:15 UTC |
Blanchard Cheryl RDirector
|
GrantCommon Stock | 3,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-006411 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,624 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest immediately prior to the Anika Therapeutics, Inc. 2019 Annual Meeting of Stockholders. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 20:05 UTC |
Darling Joseph GDirector · President and CEO; Director
|
Tax withholdingCommon Stock | 548 | $53.49 | $29,312.52 |
DisclosureSEC source: 0001171843-18-001902 · form4.xml · nonDerivative · entry 2 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,436 F2 · shares: Reflects an aggregate of 548 shares of common stock retained by the Issuer to satisfy tax withholding obligations. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 20:05 UTC |
Darling Joseph GDirector · President and CEO; Director
|
GrantCommon Stock | 7,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-001902 · form4.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,984 F1 · security: Restricted stock awards vest in four equal annual installments on March 9, 2018, March 9, 2019, March 9, 2020, and March 9, 2021. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 21:07 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,788 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001659 · formfour.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 7,788 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.